The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.

Although cyclin dependent kinase (CDK)-2 is known to be dispensable for the growth of most tumors, it is thought to be important for the proliferation of melanoma cells, where its expression is controlled by the melanocyte-lineage specific transcription factor MITF. Treatment of a panel of melanoma...

Full description

Bibliographic Details
Main Authors: Brijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, Mercedes Lioni, Min Xiao, Jun Kong, Clemens Krepler, Adina Vultur, Keith T Flaherty, Katherine L Nathanson, Keiran S M Smalley, Meenhard Herlyn
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3601112?pdf=render